$517.16
0.87% yesterday
Nasdaq, May 20, 10:06 pm CET
ISIN
US45168D1046
Symbol
IDXX
Sector

IDEXX Laboratories Stock price

$517.16
+110.51 27.18% 1M
+98.55 23.54% 6M
+103.72 25.09% YTD
-12.91 2.44% 1Y
+144.93 38.94% 3Y
+221.62 74.99% 5Y
+448.59 654.21% 10Y
Nasdaq, Closing price Tue, May 20 2025
-4.52 0.87%
ISIN
US45168D1046
Symbol
IDXX
Sector

Key metrics

Market capitalization $41.59b
Enterprise Value $42.49b
P/E (TTM) P/E ratio 47.79
EV/FCF (TTM) EV/FCF 50.12
EV/Sales (TTM) EV/Sales 10.81
P/S ratio (TTM) P/S ratio 10.58
P/B ratio (TTM) P/B ratio 28.84
Revenue growth (TTM) Revenue growth 5.56%
Revenue (TTM) Revenue $3.93b
EBIT (operating result TTM) EBIT $1.15b
Free Cash Flow (TTM) Free Cash Flow $847.70m
Cash position $163.97m
EPS (TTM) EPS $10.82
P/E forward 42.55
P/S forward 10.06
EV/Sales forward 10.28
Short interest 4.66%
Show more

Create a Free Account to create an IDEXX Laboratories alert.

Set up alerts on Stock Price, Dividend Yield, Valuation (e.g. P/E or EV/Sales) or Strategy Scores and sit back and relax.

IDEXX Laboratories Stock Analysis

Unlock Scores for Free

Analyst Opinions

13 Analysts have issued a IDEXX Laboratories forecast:

8x Buy
62%
4x Hold
31%
1x Sell
8%

Analyst Opinions

13 Analysts have issued a IDEXX Laboratories forecast:

Buy
62%
Hold
31%
Sell
8%

Financial data from IDEXX Laboratories

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
3,932 3,932
6% 6%
100%
- Direct Costs 1,521 1,521
2% 2%
39%
2,411 2,411
8% 8%
61%
- Selling and Administrative Expenses 903 903
12% 12%
23%
- Research and Development Expense 226 226
14% 14%
6%
1,282 1,282
4% 4%
33%
- Depreciation and Amortization 134 134
15% 15%
3%
EBIT (Operating Income) EBIT 1,148 1,148
3% 3%
29%
Net Profit 895 895
3% 3%
23%

In millions USD.

Don't miss a Thing! We will send you all news about IDEXX Laboratories directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

IDEXX Laboratories Stock News

Neutral
Seeking Alpha
6 days ago
IDEXX Laboratories, Inc. delivered strong Q1 FY25 results with 4.7% organic revenue and 7% adjusted EPS growth, despite weak US clinical visits. I see catalysts ahead: potential U.S. tax cuts, normalization of consumer spending, and robust pricing power supporting profit growth. Management guides for 6%-9% organic revenue and 8%-12% adjusted EPS growth in FY25; I model 8.2% revenue growth and m...
Neutral
Business Wire
7 days ago
WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced that Andrew Emerson, Executive Vice President and Chief Financial Officer, and Tina Hunt, Executive Vice President, Global Strategy and Commercial, will participate in a fireside chat at the Stifel Jaws & Paws Conference on Wednesday, May 28, 2025 from 10:55 ...
Neutral
Seeking Alpha
20 days ago
IDEXX Laboratories, Inc. (NASDAQ:IDXX ) Q1 2025 Earnings Conference Call May 1, 2025 8:30 AM ET Company Participants Andrew Emerson - EVP, CFO and Treasurer Jay Mazelsky - President and CEO Conference Call Participants Michael Ryskin - Bank of America Erin Wright - Morgan Stanley Jon Block - Stifel Brandon Vazquez - William Blair Dan Clark - Leerink Partners David Westenberg - Piper Sandler Nav...
More IDEXX Laboratories News

Company Profile

IDEXX Laboratories, Inc. engages in the development, manufacture, and distribution of products and services for the animal veterinary, livestock and poultry, dairy and water testing markets. It operates through the following segments: CAG, Water, LPD, and Other. The CAG segment develops, designs, manufactures, and distributes products and performs services for veterinarians and the biomedical analytics market, primarily related to diagnostics and information management. The Water segment develops, designs, manufactures, and distributes a range of products used in the detection of various microbiological parameters in water. The LPD segment develops, designs, manufactures, and distributes diagnostic tests and related instrumentation and performs services, which are used to manage the health status of livestock and poultry, to improve producer, and to ensure the quality and safety of milk and food. The Other operating segment combines and presents products for the human point-of-care medical diagnostics market with its out-licensing arrangements. The company was founded by David Evans Shaw on December 19, 1983 and is headquartered in Westbrook, ME.

Head office United States
CEO Jonathan Mazelsky
Employees 11,000
Founded 1983
Website www.idexx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today